CAS NO: | 1449598-06-4 |
生物活性 | RG7800 is aSMN2splicing modifier. RG7800 has the potential for spinal muscular atrophy treatment. | ||||||||||||||||
体外研究 (In Vitro) | RG7800 increases the SMN protein level via induction of alternative splicing of the SMN2 mRNA. RG7800 is shown to promote the inclusion of exon 7 in SMN2 mRNA, generating full-length mRNAin vitrousing fibroblasts from an SMA type I patient[1]. | ||||||||||||||||
体内研究 (In Vivo) | RG7800 shows favorable drug metabolism and pharmacokinetic profile in the rat and in cynomolgus monkey with good oral bioavailability. In SMA mouse model, treatment of RG7800 shows a clear dose dependent increase in SMN protein levels. Mice treated with RG7800 demonstrate a dose dependent increase in survival beginning at the low dose (0.3/1 mg/kg). In the middle and high dose groups (1/3 and 3/10 mg/kg, respectively), approximately 80–90% survive beyond PND50/PND60 with profound body weight gain when the study is terminated. RG7800 dose-dependently corrects SMN2 splicing by including exon 7 to create FL mRNA, suggesting that RG7800 corrects alternative splicing of the human SMN2 gene in the brain of transgenic SMA model mice, leading to an increase of the SMN protein in the brain[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 416.52 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C24H28N6O | ||||||||||||||||
CAS 号 | 1449598-06-4 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: Ethanol : 2.5 mg/mL(6.00 mM;Need ultrasonic) DMSO : 1.4 mg/mL(3.36 mM;Need ultrasonic and warming) H2O : 1.25 mg/mL(3.00 mM;ultrasonic and adjust pH to 3 with HCl) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |